Lung Ultrasound Offers Simple Screening for Deadly Scleroderma Complications

Scleroderma patients now have access to a simple screening tool that could save lives by detecting deadly lung complications early. This autoimmune disease causes tissue hardening and scarring, with pulmonary arterial hypertension and interstitial lung disease being the primary causes of death.

Italian researchers studied 72 scleroderma patients using lung ultrasound, a non-invasive technique that measures B-lines - indicators of lung fluid and scarring. They compared results with traditional methods including CT scans, pulmonary function tests, and echocardiograms.

The results were remarkable: lung ultrasound achieved 100% sensitivity for detecting both conditions. Fewer than 6 B-lines completely ruled out pulmonary arterial hypertension, while fewer than 5 B-lines excluded interstitial lung disease. Conversely, more than 15 B-lines indicated lung scarring with 88.9% sensitivity and 82.5% specificity.

This breakthrough matters because early detection enables timely treatment, potentially extending lifespan and improving quality of life for scleroderma patients. The test is portable, radiation-free, and significantly less expensive than CT scans or invasive procedures currently used for diagnosis.

However, this was a single-center study with 72 patients, limiting generalizability. The technique requires trained operators and may not detect very early disease stages. Despite these limitations, lung ultrasound represents a major advancement in scleroderma care, offering hope for the estimated 300,000 Americans living with this challenging autoimmune condition.